Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s ...

Kyle Bryant was diagnosed with Friedreich's Ataxia, or FA, at 17 years old. Friedreich's Ataxia is a a rare neuromuscular disease that affects 1 in 50,000 people. Over the last ...

Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $19 and keeps an Outperform rating on the shares. The firm ...

Citi says a share overhang has been removed after Larimar Therapeutics (LRMR) announced it has received FDA alignment on an accelerated ...

Shares of clinical-stage genetic medicine company Lexeo Therapeutics, Inc. soared over 50% on Monday, marking their best day ...

Dunlavin was alive with the sounds of music and song when the community came together at St Nicholas Church of Ireland for a ...

NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine ...

Importantly, we are enthusiastic about the recent FDA interactions and their openness to consider skin frataxin (FXN) ...

In addition, I think the recognition across all diseases where not everyone is going to be an expert in FA, and people can refer readily to tertiary care centers and even ordinary care centers that ...

A young Retford woman has praised the care and support received from a local children’s hospice for giving her the confidence ...

Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, ...